Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Ophthalmic biotech company developing and commercializing therapies and devices for eye conditions, focused on China and Asia.
Arctic Vision is a Shanghai, China-based clinical-stage ophthalmic biotechnology company that develops and commercializes therapies and medical devices for eye conditions such as retinal diseases and dry eye. The business acquires regional licensing rights to late-stage ophthalmic drugs and advances them through clinical trials and regulatory approval for the broader Asian healthcare market. The enterprise recently expanded its clinical portfolio into intraocular lenses and refractive platforms through the strategic acquisition of a specialized ophthalmic device business. Backed by over $140 million in total venture funding, including a Series B round, the company has secured capital from lead investors including Tencent, Loyal Valley Capital, and Octagon Capital. The firm also maintains strategic licensing partnerships with pharmaceutical developers such as Clearside Biomedical to distribute proprietary medical treatments. Arctic Vision was founded in 2019 by Dr. Eddy Wu.
Arctic Vision has raised $100.0M across 1 funding round.
Arctic Vision has raised $100.0M in total across 1 funding round.
Arctic Vision is a China-based ophthalmic biotech company developing breakthrough therapies for eye diseases, with a portfolio spanning pre-clinical to commercial-stage products.[1][2][3] It serves patients in China, Asia, and globally by addressing unmet needs in conditions like macular degeneration, dry eye, macular edema, and uveitis, backed by top-tier investors and led by industry veterans.[1][2] The company focuses on innovative drug delivery and therapies, such as licensing XIPERE™ (ARVN001) from Clearside Biomedical for uveitis-related macular edema and diabetic macular edema, positioning it as China's first innovative ophthalmology-focused biotech with strong growth momentum through partnerships and clinical preparations.[2][4]
Arctic Vision was founded in 2019 by Dr. Eddy Wu, who serves as Chairman and CEO, drawing from his extensive experience in biotechnology, including his prior role as Head of Terns China Biotechnology where he oversaw R&D and management.[1][2] Key leaders include Dr. Qing Liu, VP of Clinical & Regulatory Affairs with 18 years in ophthalmology from roles at Alcon and Allergan, and York Chen, VP of Operations & Commercial Planning with 21 years in ophthalmic sales and marketing, previously heading Allergan China's eye care business.[1][2] The idea emerged from the rapid growth of ophthalmology in China—e.g., 34 million with macular degeneration and 28 million with dry eye—prompting the veteran team to bridge global innovations to Chinese patients; the name "Arctic Vision" symbolizes animals' adaptive vision in extreme conditions.[2] Early traction included a deal with Clearside Biomedical for XIPERE™, a suprachoroidal delivery therapy, with clinical trials underway.[2][4]
Arctic Vision rides the wave of China's exploding ophthalmology market, the fastest-growing disease segment in 2019, driven by aging populations and rising conditions like macular degeneration affecting tens of millions.[2] Timing aligns with China's push for biotech self-sufficiency and imported innovations, as global players like Clearside and Bausch + Lomb partner for localized therapies amid regulatory streamlining for eye drugs.[2][4] Market forces favoring it include unmet needs in back-of-eye diseases, novel delivery tech bypassing traditional limitations, and Asia's underserved patients; it influences the ecosystem by pioneering China-centric ophthalmic innovation, fostering investor interest and clinical advancements that could expand globally.[1][2][4]
Arctic Vision is poised for expansion with ongoing clinical trials for XIPERE™ in uveitis and diabetic macular edema, plus partnerships signaling pipeline growth in presbyopia, myopia, and neuromodulation.[2][4] Trends like AI-enhanced diagnostics, gene therapies, and precision delivery will shape its path, amplified by China's biotech incentives and aging demographics. Its influence may evolve from regional pioneer to global contender, humanizing vision care as its "Arctic" namesake adapts to challenges—delivering therapies where need meets innovation.[1][2]
Arctic Vision has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2021 | $100M Series B | ROY XIE | Cventures, Adrian Cheng, Morningside Ventures, NAN Fung Life Sciences, Octagon Capital, Pivotal Bioventure Partners China, Tencent Holdings | Announced |
Arctic Vision has raised $100.0M in total across 1 funding round.
Arctic Vision's investors include Roy Xie, CVentures, Adrian Cheng, Morningside Ventures, Nan Fung Life Sciences, Octagon Capital, Pivotal bioVenture Partners China, Tencent.